Drug Repurposing for COVID-19: Ethical Considerations and Roadmaps

10Citations
Citations of this article
61Readers
Mendeley users who have this article in their library.

Abstract

While the world rushed to develop treatments for COVID-19, some turned hopefully to drug repurposing (drug repositioning). However, little study has addressed issues of drug repurposing in emergency situations from a broader perspective, taking into account the social and ethical ramifications. When drug repurposing is employed in emergency situations, the fairness of resource distribution becomes an issue that requires careful ethical consideration.This paper examines the drug repurposing in emergency situations focusing on the fairness using Japanese cases. Ethical issues under these circumstances addressed by the authors include: maintaining the evidence level, integrity of clinical research ethics, and voluntary consent by original indication patients. In order to address these issues, they argue that rapid accumulation of ethically and scientifically valid evidence is required, as is obtaining information on resource quantity.

Cite

CITATION STYLE

APA

Ino, H., Nakazawa, E., & Akabayashi, A. (2021). Drug Repurposing for COVID-19: Ethical Considerations and Roadmaps. Cambridge Quarterly of Healthcare Ethics, 30(1), 51–58. https://doi.org/10.1017/S0963180120000481

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free